Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research • Monday
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q FilingBusiness Wire • 10/19/26
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual MeetingBusiness Wire • 10/16/26
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowZacks Investment Research • 10/14/26
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending StockZacks Investment Research • 10/02/26
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology ConferenceBusiness Wire • 10/01/26
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine DeviceBusiness Wire • 09/14/26
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 09/08/26
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial AvailabilityBusiness Wire • 08/11/26
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/31/26
New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1Business Wire • 07/24/26
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q FilingBusiness Wire • 07/16/26
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGNBusiness Wire • 06/24/26
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVABusiness Wire • 06/23/26
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine DeviceBusiness Wire • 06/22/26
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in CanadaBusiness Wire • 06/18/26
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19Zacks Investment Research • 06/12/26
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)Newsfile Corp • 06/02/26
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast AsiaGlobeNewsWire • 05/21/26